RGNX Valuation

Regenxbio Inc

Add to Watchlist

Advanced Chart

12.770

-0.05(-0.390%)1D

RGNX Relative Valuation

RGNX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RGNX is overvalued; if below, it's undervalued.

Historical Valuation

Regenxbio Inc (RGNX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 12.77 is considered Overvalued compared with the five-year average of 2.85. The fair price of Regenxbio Inc (RGNX) is between 3.83 to 9.40 according to relative valuation methord. Compared to the current price of 12.77 USD , Regenxbio Inc is Overvalued By 35.86%.

Relative Value

Fair Zone

3.83-9.40

Current Price：12.77

35.86%

Overvalued

-3.94

Trailing

Forward

-7.73

EV/EBITDA

Regenxbio Inc. (RGNX) has a current EV/EBITDA of -7.73. The 5-year average EV/EBITDA is -2.09. The thresholds are as follows: Strongly Undervalued below -12.86, Undervalued between -12.86 and -7.48, Fairly Valued between 3.29 and -7.48, Overvalued between 3.29 and 8.67, and Strongly Overvalued above 8.67. The current Forward EV/EBITDA of -7.73 falls within the Undervalued range.

-4.06

EV/EBIT

Regenxbio Inc. (RGNX) has a current EV/EBIT of -4.06. The 5-year average EV/EBIT is -5.83. The thresholds are as follows: Strongly Undervalued below -27.14, Undervalued between -27.14 and -16.48, Fairly Valued between 4.82 and -16.48, Overvalued between 4.82 and 15.48, and Strongly Overvalued above 15.48. The current Forward EV/EBIT of -4.06 falls within the Historic Trend Line -Fairly Valued range.

12.77

Regenxbio Inc. (RGNX) has a current PS of 12.77. The 5-year average PS is 6.13. The thresholds are as follows: Strongly Undervalued below -0.83, Undervalued between -0.83 and 2.65, Fairly Valued between 9.61 and 2.65, Overvalued between 9.61 and 13.09, and Strongly Overvalued above 13.09. The current Forward PS of 12.77 falls within the Overvalued range.

13.71

P/OCF

Regenxbio Inc. (RGNX) has a current P/OCF of 13.71. The 5-year average P/OCF is -8.13. The thresholds are as follows: Strongly Undervalued below -78.03, Undervalued between -78.03 and -43.08, Fairly Valued between 26.82 and -43.08, Overvalued between 26.82 and 61.77, and Strongly Overvalued above 61.77. The current Forward P/OCF of 13.71 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Regenxbio Inc. (RGNX) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.89. The thresholds are as follows: Strongly Undervalued below -117.48, Undervalued between -117.48 and -58.29, Fairly Valued between 60.08 and -58.29, Overvalued between 60.08 and 119.27, and Strongly Overvalued above 119.27. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Regenxbio Inc (RGNX) has a current Price-to-Book (P/B) ratio of 3.01. Compared to its 3-year average P/B ratio of 1.87 , the current P/B ratio is approximately 61.29% higher. Relative to its 5-year average P/B ratio of 2.18, the current P/B ratio is about 38.01% higher. Regenxbio Inc (RGNX) has a Forward Free Cash Flow (FCF) yield of approximately -14.06%. Compared to its 3-year average FCF yield of -28.39%, the current FCF yield is approximately -50.47% lower. Relative to its 5-year average FCF yield of -16.82% , the current FCF yield is about -16.42% lower.

3.01

P/B

Median3y

1.87

Median5y

2.18

-14.06

FCF Yield

Median3y

-28.39

Median5y

-16.82

Competitors Valuation Multiple

The average P/S ratio for RGNX's competitors is 7.44, providing a benchmark for relative valuation. Regenxbio Inc Corp (RGNX) exhibits a P/S ratio of 12.77, which is 71.68% above the industry average. Given its robust revenue growth of -4.20%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Compass Therapeutics Inc.

Esperion Therapeutics Inc

Astria Therapeutics Inc

12.63

712.77M

MLTX.O

MoonLake Immunotherapeutics

10.10

648.73M

Performance Decomposition

Market capitalization of RGNX increased by 28.73% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -237.67 to -331.81.

The secondary factor is the Revenue Growth, contributed -4.20%to the performance.

Overall, the performance of RGNX in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-4.20%

22.30M → 21.36M

Revenue Growth

39.61%

-237.67 → -331.81

Margin Expansion

-6.68%

-3.99 → -3.72

P/E Change

28.73%